{
  "fullName": "K. S. Shaji",
  "slug": "k-s-shaji",
  "title": "MD",
  "specialty": "Dementia research",
  "geography": {
    "country": "Global",
    "city": "Unknown",
    "region": "Unknown"
  },
  "status": "LIVING",
  "tier": "UNRANKED",
  "rankingScore": 28,
  "hIndex": 134,
  "yearsActive": 0,
  "verifiedSurgeries": 0,
  "livesSaved": 0,
  "biography": "K. M. Shaji is an Indian politician belonging to the Indian Union Muslim League. He is the president of Muslim Youth League in Kerala, a secretariat member of the League, and the treasurer of the Muslim League parliamentary party.",
  "aiSummary": "K. S. Shaji is a dementia research specialist with an H-index of 134 at Psychiatry (Member). Has been published in The Lancet Oncology, Nature Reviews Disease Primers, New England Journal of Medicine. Based in Unknown, Unknown, Global.",
  "techniquesInvented": [],
  "hasInvention": false,
  "education": [
    "Psychiatry"
  ],
  "socialMedia": {},
  "affiliations": [
    {
      "hospitalName": "Psychiatry",
      "role": "Member",
      "hospitalUrl": "#"
    }
  ],
  "medicalSpecialty": [
    "Dementia research"
  ],
  "knowsAbout": [],
  "citations": [
    {
      "title": "International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma",
      "journal": "The Lancet Oncology",
      "year": 2014,
      "citationCount": 4698,
      "doi": "10.1016/s1470-2045(14)70442-5",
      "sourceUrl": "https://doi.org/10.1016/s1470-2045(14)70442-5",
      "verified": true
    },
    {
      "title": "The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms",
      "journal": "Leukemia",
      "year": 2022,
      "citationCount": 3330,
      "doi": "10.1038/s41375-022-01620-2",
      "sourceUrl": "https://doi.org/10.1038/s41375-022-01620-2",
      "verified": true
    },
    {
      "title": "International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma",
      "journal": "The Lancet Oncology",
      "year": 2016,
      "citationCount": 2834,
      "doi": "10.1016/s1470-2045(16)30206-6",
      "sourceUrl": "https://doi.org/10.1016/s1470-2045(16)30206-6",
      "verified": true
    },
    {
      "title": "Improved survival in multiple myeloma and the impact of novel therapies",
      "journal": "Blood",
      "year": 2007,
      "citationCount": 2234,
      "doi": "10.1182/blood-2007-10-116129",
      "sourceUrl": "https://doi.org/10.1182/blood-2007-10-116129",
      "verified": true
    },
    {
      "title": "Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group",
      "journal": "Journal of Clinical Oncology",
      "year": 2015,
      "citationCount": 2100,
      "doi": "10.1200/jco.2015.61.2267",
      "sourceUrl": "https://doi.org/10.1200/jco.2015.61.2267",
      "verified": true
    },
    {
      "title": "Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients",
      "journal": "Leukemia",
      "year": 2013,
      "citationCount": 1364,
      "doi": "10.1038/leu.2013.313",
      "sourceUrl": "https://doi.org/10.1038/leu.2013.313",
      "verified": true
    },
    {
      "title": "The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee",
      "journal": "Blood",
      "year": 2022,
      "citationCount": 1340,
      "doi": "10.1182/blood.2022015851",
      "sourceUrl": "https://doi.org/10.1182/blood.2022015851",
      "verified": true
    },
    {
      "title": "Multiple myeloma",
      "journal": "Nature Reviews Disease Primers",
      "year": 2017,
      "citationCount": 1120,
      "doi": "10.1038/nrdp.2017.46",
      "sourceUrl": "https://doi.org/10.1038/nrdp.2017.46",
      "verified": true
    },
    {
      "title": "Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study",
      "journal": "Blood",
      "year": 2009,
      "citationCount": 1103,
      "doi": "10.1182/blood-2008-12-194241",
      "sourceUrl": "https://doi.org/10.1182/blood-2008-12-194241",
      "verified": true
    },
    {
      "title": "Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements",
      "journal": "Journal of Clinical Oncology",
      "year": 2012,
      "citationCount": 1092,
      "doi": "10.1200/jco.2011.38.5724",
      "sourceUrl": "https://doi.org/10.1200/jco.2011.38.5724",
      "verified": true
    },
    {
      "title": "Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma",
      "journal": "New England Journal of Medicine",
      "year": 2016,
      "citationCount": 1034,
      "doi": "10.1056/nejmoa1516282",
      "sourceUrl": "https://doi.org/10.1056/nejmoa1516282",
      "verified": true
    },
    {
      "title": "Promiscuous Mutations Activate the Noncanonical NF-ÎºB Pathway in Multiple Myeloma",
      "journal": "Cancer Cell",
      "year": 2007,
      "citationCount": 980,
      "doi": "10.1016/j.ccr.2007.07.003",
      "sourceUrl": "https://doi.org/10.1016/j.ccr.2007.07.003",
      "verified": true
    },
    {
      "title": "Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma",
      "journal": "New England Journal of Medicine",
      "year": 2019,
      "citationCount": 944,
      "doi": "10.1056/nejmoa1817249",
      "sourceUrl": "https://doi.org/10.1056/nejmoa1817249",
      "verified": true
    },
    {
      "title": "New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes",
      "journal": "Journal of Clinical Oncology",
      "year": 2012,
      "citationCount": 925,
      "doi": "10.1200/jco.2011.37.7614",
      "sourceUrl": "https://doi.org/10.1200/jco.2011.37.7614",
      "verified": true
    },
    {
      "title": "Multiple Myeloma: Diagnosis and Treatment",
      "journal": "Mayo Clinic Proceedings",
      "year": 2016,
      "citationCount": 801,
      "doi": "10.1016/j.mayocp.2015.11.007",
      "sourceUrl": "https://doi.org/10.1016/j.mayocp.2015.11.007",
      "verified": true
    },
    {
      "title": "Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report",
      "journal": "Blood",
      "year": 2015,
      "citationCount": 737,
      "doi": "10.1182/blood-2014-12-615187",
      "sourceUrl": "https://doi.org/10.1182/blood-2014-12-615187",
      "verified": true
    },
    {
      "title": "Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study",
      "journal": "Leukemia",
      "year": 2011,
      "citationCount": 716,
      "doi": "10.1038/leu.2011.196",
      "sourceUrl": "https://doi.org/10.1038/leu.2011.196",
      "verified": true
    },
    {
      "title": "Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma",
      "journal": "Blood",
      "year": 2005,
      "citationCount": 643,
      "doi": "10.1182/blood-2005-07-2817",
      "sourceUrl": "https://doi.org/10.1182/blood-2005-07-2817",
      "verified": true
    },
    {
      "title": "Mesenteric Venous Thrombosis",
      "journal": "New England Journal of Medicine",
      "year": 2001,
      "citationCount": 639,
      "doi": "10.1056/nejmra010076",
      "sourceUrl": "https://doi.org/10.1056/nejmra010076",
      "verified": true
    },
    {
      "title": "Clonal competition with alternating dominance in multiple myeloma",
      "journal": "Blood",
      "year": 2012,
      "citationCount": 629,
      "doi": "10.1182/blood-2012-01-405985",
      "sourceUrl": "https://doi.org/10.1182/blood-2012-01-405985",
      "verified": true
    },
    {
      "title": "Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines",
      "journal": "Mayo Clinic Proceedings",
      "year": 2009,
      "citationCount": 622,
      "doi": "10.4065/mcp.2009.0603",
      "sourceUrl": "https://doi.org/10.4065/mcp.2009.0603",
      "verified": true
    },
    {
      "title": "Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance",
      "journal": "New England Journal of Medicine",
      "year": 2018,
      "citationCount": 605,
      "doi": "10.1056/nejmoa1709974",
      "sourceUrl": "https://doi.org/10.1056/nejmoa1709974",
      "verified": true
    },
    {
      "title": "Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy",
      "journal": "Leukemia",
      "year": 2019,
      "citationCount": 594,
      "doi": "10.1038/s41375-019-0435-7",
      "sourceUrl": "https://doi.org/10.1038/s41375-019-0435-7",
      "verified": true
    },
    {
      "title": "Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma",
      "journal": "Blood",
      "year": 2017,
      "citationCount": 517,
      "doi": "10.1182/blood-2017-06-788786",
      "sourceUrl": "https://doi.org/10.1182/blood-2017-06-788786",
      "verified": true
    },
    {
      "title": "Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group",
      "journal": "The Lancet Oncology",
      "year": 2017,
      "citationCount": 502,
      "doi": "10.1016/s1470-2045(17)30189-4",
      "sourceUrl": "https://doi.org/10.1016/s1470-2045(17)30189-4",
      "verified": true
    },
    {
      "title": "Management of Newly Diagnosed Symptomatic Multiple Myeloma: Updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines 2013",
      "journal": "Mayo Clinic Proceedings",
      "year": 2013,
      "citationCount": 485,
      "doi": "10.1016/j.mayocp.2013.01.019",
      "sourceUrl": "https://doi.org/10.1016/j.mayocp.2013.01.019",
      "verified": true
    },
    {
      "title": "International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma",
      "journal": "Leukemia",
      "year": 2009,
      "citationCount": 480,
      "doi": "10.1038/leu.2009.89",
      "sourceUrl": "https://doi.org/10.1038/leu.2009.89",
      "verified": true
    },
    {
      "title": "International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders",
      "journal": "The Lancet Oncology",
      "year": 2019,
      "citationCount": 470,
      "doi": "10.1016/s1470-2045(19)30309-2",
      "sourceUrl": "https://doi.org/10.1016/s1470-2045(19)30309-2",
      "verified": true
    },
    {
      "title": "Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma",
      "journal": "Blood",
      "year": 2012,
      "citationCount": 449,
      "doi": "10.1182/blood-2011-11-395749",
      "sourceUrl": "https://doi.org/10.1182/blood-2011-11-395749",
      "verified": true
    },
    {
      "title": "Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3",
      "journal": "Blood",
      "year": 2011,
      "citationCount": 448,
      "doi": "10.1182/blood-2010-10-299529",
      "sourceUrl": "https://doi.org/10.1182/blood-2010-10-299529",
      "verified": true
    },
    {
      "title": "Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma",
      "journal": "Blood",
      "year": 2007,
      "citationCount": 423,
      "doi": "10.1182/blood-2007-08-108357",
      "sourceUrl": "https://doi.org/10.1182/blood-2007-08-108357",
      "verified": true
    },
    {
      "title": "Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial",
      "journal": "The Lancet Oncology",
      "year": 2020,
      "citationCount": 390,
      "doi": "10.1016/s1470-2045(20)30525-8",
      "sourceUrl": "https://doi.org/10.1016/s1470-2045(20)30525-8",
      "verified": true
    },
    {
      "title": "Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study",
      "journal": "The Lancet",
      "year": 2010,
      "citationCount": 382,
      "doi": "10.1016/s0140-6736(10)60482-5",
      "sourceUrl": "https://doi.org/10.1016/s0140-6736(10)60482-5",
      "verified": true
    },
    {
      "title": "Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group",
      "journal": "Leukemia",
      "year": 2012,
      "citationCount": 376,
      "doi": "10.1038/leu.2012.336",
      "sourceUrl": "https://doi.org/10.1038/leu.2012.336",
      "verified": true
    },
    {
      "title": "Clinical Course of Patients With Relapsed Multiple Myeloma",
      "journal": "Mayo Clinic Proceedings",
      "year": 2004,
      "citationCount": 364,
      "doi": "10.4065/79.7.867",
      "sourceUrl": "https://doi.org/10.4065/79.7.867",
      "verified": true
    },
    {
      "title": "Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study",
      "journal": "Leukemia",
      "year": 2017,
      "citationCount": 348,
      "doi": "10.1038/leu.2017.138",
      "sourceUrl": "https://doi.org/10.1038/leu.2017.138",
      "verified": true
    },
    {
      "title": "Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma",
      "journal": "Leukemia",
      "year": 2007,
      "citationCount": 348,
      "doi": "10.1038/sj.leu.2404801",
      "sourceUrl": "https://doi.org/10.1038/sj.leu.2404801",
      "verified": true
    },
    {
      "title": "Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial",
      "journal": "The Lancet Oncology",
      "year": 2021,
      "citationCount": 345,
      "doi": "10.1016/s1470-2045(21)00466-6",
      "sourceUrl": "https://doi.org/10.1016/s1470-2045(21)00466-6",
      "verified": true
    },
    {
      "title": "Multiple myeloma current treatment algorithms",
      "journal": "Blood Cancer Journal",
      "year": 2020,
      "citationCount": 339,
      "doi": "10.1038/s41408-020-00359-2",
      "sourceUrl": "https://doi.org/10.1038/s41408-020-00359-2",
      "verified": true
    },
    {
      "title": "Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death",
      "journal": "Blood",
      "year": 2017,
      "citationCount": 324,
      "doi": "10.1182/blood-2016-11-751628",
      "sourceUrl": "https://doi.org/10.1182/blood-2016-11-751628",
      "verified": true
    },
    {
      "title": "Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma",
      "journal": "Journal of Clinical Oncology",
      "year": 2009,
      "citationCount": 320,
      "doi": "10.1200/jco.2009.23.6802",
      "sourceUrl": "https://doi.org/10.1200/jco.2009.23.6802",
      "verified": true
    },
    {
      "title": "Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline",
      "journal": "Journal of Clinical Oncology",
      "year": 2019,
      "citationCount": 316,
      "doi": "10.1200/jco.18.02096",
      "sourceUrl": "https://doi.org/10.1200/jco.18.02096",
      "verified": true
    },
    {
      "title": "Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application",
      "journal": "British Journal of Haematology",
      "year": 2004,
      "citationCount": 316,
      "doi": "10.1111/j.1365-2141.2004.05286.x",
      "sourceUrl": "https://doi.org/10.1111/j.1365-2141.2004.05286.x",
      "verified": true
    },
    {
      "title": "Prognostic Factors and Outcomes of Adults With Hemophagocytic Lymphohistiocytosis",
      "journal": "Mayo Clinic Proceedings",
      "year": 2014,
      "citationCount": 313,
      "doi": "10.1016/j.mayocp.2013.12.012",
      "sourceUrl": "https://doi.org/10.1016/j.mayocp.2013.12.012",
      "verified": true
    },
    {
      "title": "Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond",
      "journal": "Leukemia",
      "year": 2017,
      "citationCount": 301,
      "doi": "10.1038/leu.2017.329",
      "sourceUrl": "https://doi.org/10.1038/leu.2017.329",
      "verified": true
    },
    {
      "title": "Malignant primary cardiac tumors",
      "journal": "Cancer",
      "year": 2008,
      "citationCount": 299,
      "doi": "10.1002/cncr.23459",
      "sourceUrl": "https://doi.org/10.1002/cncr.23459",
      "verified": true
    },
    {
      "title": "Systemic amyloidosis from A (AA) to T (ATTR): a review",
      "journal": "Journal of Internal Medicine",
      "year": 2020,
      "citationCount": 291,
      "doi": "10.1111/joim.13169",
      "sourceUrl": "https://doi.org/10.1111/joim.13169",
      "verified": true
    },
    {
      "title": "Functional Interaction of Plasmacytoid Dendritic Cells with Multiple Myeloma Cells: A Therapeutic Target",
      "journal": "Cancer Cell",
      "year": 2009,
      "citationCount": 289,
      "doi": "10.1016/j.ccr.2009.08.019",
      "sourceUrl": "https://doi.org/10.1016/j.ccr.2009.08.019",
      "verified": true
    },
    {
      "title": "Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma",
      "journal": "Journal of Clinical Oncology",
      "year": 2019,
      "citationCount": 289,
      "doi": "10.1200/jco.19.01740",
      "sourceUrl": "https://doi.org/10.1200/jco.19.01740",
      "verified": true
    },
    {
      "title": "Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States",
      "journal": "Blood Advances",
      "year": 2017,
      "citationCount": 285,
      "doi": "10.1182/bloodadvances.2016002493",
      "sourceUrl": "https://doi.org/10.1182/bloodadvances.2016002493",
      "verified": true
    }
  ],
  "awards": [],
  "timeline": [],
  "openalexId": "https://openalex.org/A5026574827"
}